ArticleThe Journal of biological chemistry2026
Phosphatidylinositol 4-kinase α suppresses glioblastoma progression by inactivating YAP and PI3K/Akt signaling.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is one of the most malignant tumors of the central nervous system and is characterized by altered lipid metabolism. Notably, phosphatidylinositol (PI) metabolism is reprogrammed in GBM; however, its role and mechanism in GBM remain unclear. In this study, we found that phosphatidylinositol 4-kinase α (PI4Kα) (a subtype of PI4Ks) was downregulated in both low- and high-grade glioma tissues from clinical patients. Overexpressing the C terminus (1199-2102 amino acids) of PI4Kα, containing its catalytic domain (hereafter referred to as PI4Kα-CD for simplicity), in U251 and C6 cells (GBM cell lines), could significantly inhibit their proliferation and migration, whereas PI4Kα knockdown promoted their growth and migration. Mechanistically, PI4Kα inactivated YAP signaling by enhancing p-YAP (a major downstream effector of the Hippo pathway) and reducing the nuclear translocation of YAP, as well as suppressing PI3K/Akt signaling. YAP activation significantly restored the PI4Kα-CD overexpression-induced inhibitory effects on GBM growth. Finally, the growth of intracranially orthotopically transplanted PI4Kα-CD-overexpressing GBM cells in C57BL/6 mice was also suppressed through YAP signaling. Overall, these results reveal an unrecognized function of PI4Kα as a repressor in GBM progression through inactivation of YAP and PI3K/Akt signaling, thus providing a potential target for GBM treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.